



Detection Single Nucleotide Polymorphisms in UMOD Gene in Patients with Febrile UTI in Hilla Province

Umniah abd alnasser saleh hadi, Aizhar H. Hasan

Department of Biology, College of Science, University of Babylon, Iraq

Iraq. Email: umniahabdulnaser@gmail.com

Iraq. Email: azhar.hamza@gmail.com

Abstract

Uromodulin, a glycosylphosphatidylinositol anchored glycoprotein, is exclusively expressed in the thick ascending loop of Henle¹ and distal convoluted tubule² of the mammalian kidney. It is exclusively produced in the kidney and secreted into the urine. Mutations lead to uromodulin misfolding and retention in the kidney, where it might stimulate cells of immune system to cause inflammation and progression of kidney disease. Sixty one blood samples were collected from patient with febrile UTI infection whom visit Hilla Teaching hospital /Babylon /Iraq and twenty two samples as a control group. *DNA derived by PCR amplification of DNA from blood samples.* Genotyping of *uromodulin* gene was performed using a polymerase chain reaction technique, followed by DNA sequencing. Accordingly, these DNA polymorphisms were confirmed using DNA sequencing. The sequencing results showed the presence of many SNPs determined in the UMOD gene .

Key words:- febrile UTI , Uromodulin , SNP

Introduction

UMOD, also known as Tamm–Horsfall protein, is a glycoprotein expressed exclusively by renal tubular cells lining the thick ascending limb of the loop of Henle (El-Achkar & Wu,2012). and is the most abundant protein excreted in the urine under physiologic conditions(Bongiovanni etal,2015). Although its physiologic functions have hitherto remained unclear until recently, substantial progress has been made in highlighting the importance of UMOD in the pathophysiology of medullary cystic kidney disease, UTI, and nephrolithiasis (Iorember & Vehaskari



,2014).For instance, UMOD is believed to be renoprotective against UTI and stone formation and has also been linked to fluid and electrolyte homeostasis, as well as to kidney innate immunity(Rampoldi et al,2011). Furthermore, there has been a renewed interest in the role of UMOD in kidney injury(El-Achkar & Wu,2012). and in the link of its mutations with the etiology of uromodulin-associated kidney diseases (UAKD): medullary cystic disease type 2, familial juvenile hyperuricemic nephropathy, and glomerulocystic kidney disease(Iorember & Vehaskari ,2014).

The common features of these diseases are the autosomal dominant inheritance, insignificant urine sediment, and slow progression to end-stage renal disease, while they are also frequently associated with hyperuricemia and gout (Iorember & Vehaskari ,2014). Other characteristic features include progressive tubulointerstitial damage, impaired urinary concentrating ability, and renal cysts, with evidence pointing at intracellular accumulation of mutant UMOD (due to delayed intracellular trafficking) as a fundamental primary event in the pathogenesis of UAKD(Fugiel et al,2013).

Interestingly, the paradigm of UMOD as a trigger in kidney injury has been challenged by new evidence from a murine model showing a protective role for this protein in AKI, possibly through downregulation of interstitial inflammation(El-Achkar & Wu,2012). UMOD is expressed by the cells of the thick ascending limb of the loop of Henle, lower UMOD serum levels may thus reflect a reduction in number or function of these cells in CKD(Risch et al,2014).

Recently highlighted heredity investigations that proved the importance of this protein, since the uromodulin mutations were implicated in dominant tubulointerstitial viscus ill health (Dahan et al,2003; Trudu et al,2013).



Several genome-wide association studies (GWASs) investigated a lot of *UMOD* genetic risk loci (such as rs12917707, rs6497476, and rs4293393) were concerned with estimated glomerular filtration rate (eGFR) related to chronic kidney disease (CKD) or upset (Regele et al, 2015). In 2009, the single-nucleotide polymorphisms (SNPs) in the *UMOD* gene were investigated among a big cohort of patients suffering from CKD and found that these SNPs may be implicated to the genetic standing in end-stage renal disease (ESRD), SNPs are single-nucleotide variations that have arisen randomly over time in the human genome, and it is mostly occurring in noncoding regions (Reznichenko et al, 2008). The aim of the study was to analyze single-nucleotide polymorphism (SNP) in the promoter region of the *UMOD* gene in patients suffering from febrile UTI using polymerase chain reaction –sequencing technique.

Materials and methods

Sampling

Sixty one blood samples were collected from patient with febrile UTI infection whom visit Hilla Teaching hospital /Babylon /Iraq and twenty two samples as a control group.

DNA Extraction

The genomic DNA collected from blood and all samples were tested with the nanodrop spectrophotometer to verify and quantify the purity of DNA by measuring absorption in (260/280 nm) according to blood DNA Favorgen- Taiwan extraction kits.

Primer



The targeted sites of the *UMOD* promoter regions were amplified using design-specific primers (Bioneer, IDTDNA - USA). Forward: 5'-GGGGATCTTCTCCCTTGGC-3'; Reverse: 5'-CAACCCACGTCACAGGGAAG-3' (Isam et al, 2018).

PCR was carried out in the reaction mixture containing 1 µl from forward and reverse primers, 12.5 µl of Green Master Mix, and 3 µl of genomic DNA, and the volume of reaction was completed up to 20 µl by adding 2.5 µl of the nuclease-free water. Amplification was carried out in a TRIO Thermal Cycler (Biometra, Germany) programmed for 2 min pre-denaturation at 94°C; 30 cycles, 5 min at 94°C (DNA denaturation), 1 min at 61°C (annealing), and 1 min at 72°C (extended); and a final extension of 5 min. PCR products were electrophoresed using gel electrophoresis (Cleaver Scientific - UK) in 1% agarose at 75 V for 1 hour and visualized by ethidium bromide. Photos were taken using gel documentation system (Cleaver Scientific - UK).

Sequencing of amplified DNA fragment

The amplified fragments were purified using the protocol suggested by MacroGen sequencing company (MacroGen - Korea), and then, they were sequenced using each primer pair. The sequences of the gene fragments analyzed were aligned by multiple sequence alignment program, according to BioEdit, with the sequences published in the Gen Bank database taken as a reference to identify the polymorphisms.

Results

Genotyping promoter region of the *UMOD* gene

The genomic DNA has been amplified with unique primer for genotyping the *UMOD* gene and is done in optimum conditions by thermo-cyclers. Results showed that the *UMOD* gene target sequence in agarose gel is present in a single band (317 bp) (Fig. 1)




Fig. 1 Agarose gel electrophoresis of amplified products of *UOMD* promoter region of patients with chronic kidney disease and end-stage renal disease and healthy control groups. M: DNA size marker; lane 1-11 refers to the patterns of amplified products of *UMOD* promoter region (317 bp). Electrophoresis conditions: 1% agarose, 75 V, 20 mA for 120 min. The band staining with ethidium bromide




Fig. 2: Sequences alignment ID: AY061638.1 results for Homo sapiens, *UOMD* gene promoter region by Bio Edit program version 7.2.5.

Discussion



The genomic DNA was amplified using special primers for *UMOD* gene genotyping. The findings show that one band (317 bp) of the *UMOD* gene target sequence has been present.

The biological effectiveness of uromodulin is still rather mysterious, and it may have ability to conserve water/electrolyte balance inside the TAL depending on its gelification and physicochemical characteristics. In addition, it has protective effects against urinary tract infections (UTI) in Umod knockout mice (Bates et al, 2004). This function is due to the ability of the uromodulin through its rich-mannose moiety to bind with the fimbria of bacteria such as *Escherichia coli* (Serafini-Cessi et al, 2003).

variation in UMOD, some other variations have also been studied in diseases with renal impairment. Gómez *et al* found a missense mutation p.V458L in which leucine variant was more frequent in individuals with reduced GFR as compared to healthy individuals with normal GFR. Associations of *UMOD* rs13333226 G allele with hypertension,. However, Cui *et al* reported association of rs13333226G allele with slower decline in renal function in individuals with CKD. A study of *UMOD* variant rs12917707 in Italian diabetic cohort, no association was found with renal function (Prudente et al, 2016).

Depending on the finding of Köttgen *et al.* (2010) who revealed that the SNP rs4293393 positioned at 300 bp upstream of the uromodulin encoding gene, is related to increasing a risk of febrile UTI in the Icelandic population. The rs4293393 variation was additionally connected with uric acid levels increasing and amplified risk of arthritis, a distinction with a lower danger of creation of calcium-containing urinary organ stones within the Icelandic population. The relationship between the rs4293393 or rs12917707 variants with creatinine levels increasing was definitely in a



meta-analysis of five Europeans isolates (EUROSPAN) and at intervals the large European cluster (Chambers et al., 2010).

The human GWASs all systematically show the uromodulin decreasing alleles (of rs12917707, rs4293393, rs13333226) to be related to higher GFR (Kottgen *et al.*, 2009). Though lower GFR could indicate nephritic injury and reduced functioning tubular mass leading to lower urinary uromodulin as seen in clinical studies, the single-nucleotide polymorphism–GFR association implies a potential causative association between UMOD variables on GFR, If this were the case, then absence of UMOD in UMOD^{–/–} mice should also show high GFR. However the UMOD^{–/–} mice show significantly decreased urinary GFR compared with wild-type mice, one suggested explanation is related to the finding that adjusted 24-hour uromodulin excretion (reported as µg/ ml of creatinine clearance) is increased in patients with UTI and that 24-hour uromodulin excretion increases in diabetic patients with early kidney disease but without a significantly decreased GFR (Padmanabhan *et al.*, 2010).

References

- Bates, J. M., Raffi, H. M., Prasad, K., Mascarenhas, R., Laszik, Z., Maeda, N., ... & Koning, J. (2004). Tamm-Horsfall protein knockout mice are more prone to urinary tract infection: Rapid communication. *Kidney International, 65*(3), 791–797.
- Bongiovanni, C., Magrini, L., Salerno, G., Gori, C. S., Cardelli, P., Hur, M., ... & Testa, F. (2015). Serum cystatin C for the diagnosis of acute kidney



injury in patients admitted in the emergency department. *Disease Markers, 2015*, 416059. <https://doi.org/10.1155/2015/416059>

Chambers, J. C., Zhang, W., Lord, G. M., ... & Kooner, J. S. (2010). Genetic loci influencing kidney function and chronic kidney disease. *Nature Genetics, 42*(5), 373–375. <https://doi.org/10.1038/ng.573>

Cui, L., Bai, Y., Xu, J., Zhang, J., Zhang, H., Zhang, S., ... & Wang, W. (2015). Single-nucleotide polymorphism of the UMOD promoter is associated with the outcome of chronic kidney disease patients. *Biomed Reports, 3*(5), 588–592. <https://doi.org/10.3892/br.2015.497>

Dahan, K., Devuyst, O., Smaers, M., Vertommen, D., Loute, G., Poux, J. M., ... & Schaeffer, C. (2003). A cluster of mutations in the UMOD gene causes familial juvenile hyperuricemic nephropathy with abnormal expression of uromodulin. *Journal of the American Society of Nephrology, 14*(10), 2883–2893. <https://doi.org/10.1097/01.ASN.0000090550.65602.3E>

El-Achkar, T. M., & Wu, X. R. (2012). Uromodulin in kidney injury: An instigator, bystander, or protector? *American Journal of Kidney Diseases, 59*(4), 452–461. <https://doi.org/10.1056/NEJMoa1802274>



- Fugiel, A., Kuzniewski, M., & Fedak, D. (2013). Uromodulin – can it be a new marker of kidney damage? **Przegląd Lekarski*, 70*(11), 976–982.
- Gómez, J., Díaz-Corte, C., Tranche, S., Alvarez, F., Iglesias, S., Alonso, B., ... & Modesto, P. (2015). Next generation sequencing search for uromodulin gene variants related with impaired renal function. **Molecular Biology Reports*, 42*(9), 1353–1358. <https://doi.org/10.1007/s11033-015-3952-x>
- Iorember, F. M., & Vehaskari, V. M. (2014). Uromodulin: Old friend with new roles in health and disease. **Pediatric Nephrology*, 29*(6), 1151–1158. <https://doi.org/10.1007/s00467-014-2772-1>
- Isam, Z., Omran, R., & Mahmood, A. H. (2018). Detection of single nucleotide polymorphisms in uromodulin promoter region associated with renal diseases using single-strand conformation polymorphism-polymerase chain reaction technique. **Asian Journal of Pharmaceutical and Clinical Research*, 11*(1), 205–209. <https://doi.org/10.22159/ajpcr.2018.v11i1.22063>
- Kottgen, A., Glazer, N. L., Dehghan, A., ... & Heid, I. M. (2009). Multiple loci associated with indices of renal function and chronic kidney disease. **Nature Genetics*, 41*(6), 712–717. <https://doi.org/10.1038/ng.384>



- Kottgen, A., Pattaro, C., Boger, C. A., ... & Gieger, C. (2010). New loci associated with kidney function and chronic kidney disease. *Nature Genetics, 42*(5), 376–384. <https://doi.org/10.1038/ng.574>
- Padmanabhan, S., Melander, O., Johnson, T., ... & Global BPgen Consortium. (2010). Genome-wide association study of blood pressure extremes identifies variant near UMOD associated with hypertension. *PLOS Genetics, 6*(6), e1001177. <https://doi.org/10.1371/journal.pgen.1001177>
- Prudente, S., Di Paola, R., Copetti, M., Lucchesi, D., Lamacchia, O., Pezzilli, S., ... & Loffredo, L. (2016). The rs12917707 polymorphism at the UMOD locus and glomerular filtration rate in individuals with type 2 diabetes: Evidence of heterogeneity across two different European populations. *Nephrology Dialysis Transplantation, 31*(1). <https://doi.org/10.1093/ndt/gfw262>
- Rampoldi, L., Scolari, F., Amoroso, A., Ghiggeri, G., & Devuyst, O. (2011). The rediscovery of uromodulin (Tamm-Horsfall protein): From tubulointerstitial nephropathy to chronic kidney disease. *Kidney International, 80*(3), 338–347. <https://doi.org/10.1038/ki.2011.104>
- Regele, F., Jelencsics, K., Shiffman, D., Paré, G., McQueen, M. J., Mann, J. F., ... & Rieke, J. (2015). Genome-wide studies to identify risk factors for kidney disease with a focus on patients with diabetes. *Nephrology



Dialysis Transplantation, 30*(Suppl 4), iv26–iv34.
<https://doi.org/10.1093/ndt/dfv181>

Reznichenko, A., Böger, C. A., Snieder, H., van den Born, J., de Borst, M. H., Damman, J., ... & van der Woude, F. J. (2012). UMOD as a susceptibility gene for end-stage renal disease. *BMC Medical Genetics, 13*, 78. <https://doi.org/10.1186/1471-2350-13-78>

Risch, L., Lhotta, K., Meier, D., Medina-Escobar, P., Nydegger, U. E., Risch, M., ... & Baumann, M. (2014). The serum uromodulin level is associated with kidney function. *Clinical Chemistry and Laboratory Medicine, 52*(12), 1755–1761. <https://doi.org/10.1515/cclm-2014-0362>

Serafini-Cessi, F., Malagolini, N., & Cavallone, D. (2003). Tamm-Horsfall glycoprotein: Biology and clinical relevance. *American Journal of Kidney Diseases, 42*(4), 658–676. [https://doi.org/10.1016/S0272-6386\(03\)00836-2](https://doi.org/10.1016/S0272-6386(03)00836-2)

Trudu, M., Janas, S., Lanzani, C., Debaix, H., Schaeffer, C., Ikehata, M., ... & Bianchi, S. (2013). Common noncoding UMOD gene variants induce salt-sensitive hypertension and kidney damage by increasing uromodulin expression. *Nature Medicine, 19*(12), 1655–1660. <https://doi.org/10.1038/n>